Psyence BioMed Announces US$5M PsyLabs Investment and US$9M Share Exchange
PBM has more than doubled off its 52-week low of $1.92 on elevated volume (2.1× avg).
Summary
Psyence BioMed announced a related-party investment of up to US$5 million in PsyLabs and a US$9 million share-for-share exchange that will nearly double PsyLabs' stake in PBM to 49.89%.
Key Events · Financing and Capital Events · PBM
-
US$9M Share Exchange with PsyLabs
PBM will issue 1,497,500 new common shares at US$6.00 per share (US$8.99M) to PsyLabs in exchange for 3,473 PsyLabs shares valued at US$60M implied equity valuation.
-
PsyLabs Stake Nearly Doubles to 49.89%
Post-transaction, PsyLabs' ownership of PBM rises from 30.22% to approximately 49.89%, approaching majority control in a related-party transaction.
-
US$5M Cash Investment in PsyLabs
PBM committed US$2.4 million irrevocably (936 shares at US$2,564/share) with a backstop of up to US$2.6 million in two milestone tranches, lapsing December 31, 2026.
-
Related-Party Governance Risk
The transactions are between related parties sharing directors (Jody Aufrichtig signs for both PBM and PBCII), and the US$6.00 issue price is below today's US$6.42 market price.
Analysis · PBM · Life Sciences
Psyence BioMed is issuing 1,497,500 new common shares at US$6.00 per share to PsyLabs in a value-matched exchange, while committing up to US$5 million in cash to PsyLabs. The share issuance is highly dilutive to existing holders — PsyLabs' ownership of PBM jumps from approximately 30.22% to 49.89%, approaching majority control. The US$6.00 deemed issue price is below today's US$6.42 market price, and the transaction is a related-party deal between entities sharing directors, raising governance concerns about whether terms reflect arm's-length value. The cash investment and backstop commitment also expose PBM to further funding obligations through December 2026.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $6.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $1.92 to $34.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.